Effect of granulocyte colony-stimulating factor mobilization on phenotypical and functional properties of immune cells

Exp Hematol. 2001 Apr;29(4):458-70. doi: 10.1016/s0301-472x(01)00613-0.

Abstract

Some phenotypic and functional properties of lymphocytes from bone marrow or peripheral blood stem cell donors were compared in a randomized study. Lymphocyte subsets were analyzed by immunocytometry in blood harvested from bone marrow donors (n = 27) and from peripheral blood stem cell donors before and after granulocyte colony-stimulating factor mobilization (n = 23) and in bone marrow and peripheral blood stem cell grafts. Granulocyte colony-stimulating factor mobilization increased the blood T and B, but not NK, lymphocyte counts. All lymphocyte counts were approximately 10-fold higher in peripheral blood stem cell grafts than in bone marrow grafts. Analysis of CD25, CD95, HLA-DR, and CD45RA expression shows that T-cell activation level was lower after granulocyte colony-stimulating factor mobilization. Similarly, granulocyte colony-stimulating factor reduced by twofold to threefold the percentage of interferon-gamma, interleukin-2, and tumor necrosis factor-alpha-secreting cells within the NK, NK-T, and T-cell subsets and severely impaired the potential for interferon-gamma production at the single-cell level. mRNA levels of both type 1 (interferon-gamma, interleukin-2) and type 2 (interleukin-4, interleukin-13) cytokines were approximately 10-fold lower in peripheral blood stem cell grafts than in bone marrow grafts. This reduced potential of cytokine production was not associated with a preferential mobilization of so-called "suppressive" cells (CD3+CD4-CD8-, CD3+CD8+CD56+, or CD3+TCRVA24+CD161+), nor with a modulation of killer cell receptors CD161, NKB1, and CD94 expression by NK, NK-T, or T cells. Our data demonstrate in a randomized setting that quantitative as well as qualitative differences exist between a bone marrow and a peripheral blood stem cell graft, whose ability to produce type 1 and type 2 cytokines is impaired.

Publication types

  • Clinical Trial
  • Clinical Trial, Phase III
  • Comparative Study
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • B-Lymphocytes / immunology
  • Blood Donors
  • Bone Marrow Transplantation
  • Granulocyte Colony-Stimulating Factor / pharmacology*
  • HLA-DR Antigens / analysis
  • Hematopoietic Stem Cell Transplantation
  • Humans
  • Immunophenotyping
  • Interferon-gamma / biosynthesis
  • Interferon-gamma / genetics
  • Interleukin-13 / genetics
  • Interleukin-2 / biosynthesis
  • Interleukin-2 / genetics
  • Interleukin-4 / genetics
  • Killer Cells, Natural / immunology
  • Leukocyte Common Antigens / analysis
  • Lymphocyte Activation
  • Lymphocyte Count*
  • Lymphocyte Subsets / immunology*
  • Phenotype*
  • Protein Tyrosine Phosphatase, Non-Receptor Type 1
  • RNA, Messenger / analysis
  • Receptors, Interleukin-2 / analysis
  • T-Lymphocytes / immunology
  • T-Lymphocytes, Regulatory / immunology
  • Tissue Donors
  • Tumor Necrosis Factor-alpha / biosynthesis
  • Tumor Necrosis Factor-alpha / genetics
  • fas Receptor / analysis

Substances

  • HLA-DR Antigens
  • Interleukin-13
  • Interleukin-2
  • RNA, Messenger
  • Receptors, Interleukin-2
  • Tumor Necrosis Factor-alpha
  • fas Receptor
  • Granulocyte Colony-Stimulating Factor
  • Interleukin-4
  • Interferon-gamma
  • Leukocyte Common Antigens
  • Protein Tyrosine Phosphatase, Non-Receptor Type 1